The Primary Occurrence ofBRAFV600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma | Zendy

Anna Guerra | Zendy; Maria Rosaria Sapio | Zendy; Vincenzo Marotta | Zendy; Elisabetta Campanile | Zendy; Stefania Rossi | Zendy; Irene Forno | Zendy; Laura Fugazzola | Zendy; Alfredo Budillon | Zendy; Tania Moccia | Zendy; Gianfranco Fenzi | Zendy; Mario Vitale | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Primary Occurrence ofBRAF^V600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma

Author(s) -

Anna Guerra,

Maria Rosaria Sapio,

Vincenzo Marotta,

Elisabetta Campanile,

Stefania Rossi,

Irene Forno,

Laura Fugazzola,

Alfredo Budillon,

Tania Moccia,

Gianfranco Fenzi,

Mario Vitale

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-0618

Subject(s) - neuroblastoma ras viral oncogene homolog , kras , cancer research , thyroid carcinoma , biology , mutation , papillary thyroid cancer , thyroid cancer , allele , v600e , cancer , microbiology and biotechnology , genetics , thyroid , gene

BRAF(V600E) is considered a primary event, a negative prognostic marker, and a site for pharmacological intervention in papillary thyroid carcinoma (PTC). We asked whether BRAF(V600E) can occur as a subclonal event in PTC and whether this and other oncogenes can coexist in the same tumor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research